CARECLOUD INC (CCLD) Stock Fundamental Analysis
NASDAQ:CCLD - Nasdaq - US14167R1005 - Common Stock - Currency: USD
Taking everything into account, CCLD scores 5 out of 10 in our fundamental rating. CCLD was compared to 37 industry peers in the Health Care Technology industry. CCLD has only an average score on both its financial health and profitability. CCLD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
CCLD had negative earnings in the past year.
CCLD had a positive operating cash flow in the past year.
CCLD had negative earnings in each of the past 5 years.
Of the past 5 years CCLD 4 years had a positive operating cash flow.
1.2 Ratios
CCLD's Return On Assets of -4.40% is fine compared to the rest of the industry. CCLD outperforms 75.68% of its industry peers.
CCLD's Return On Equity of -6.33% is fine compared to the rest of the industry. CCLD outperforms 78.38% of its industry peers.
The Return On Invested Capital of CCLD (14.75%) is better than 97.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -6.33% | ||
| ROIC | 14.75% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of CCLD (8.77%) is better than 89.19% of its industry peers.
CCLD's Operating Margin has improved in the last couple of years.
The Gross Margin of CCLD (45.11%) is worse than 62.16% of its industry peers.
CCLD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.77% | ||
| PM (TTM) | N/A | ||
| GM | 45.11% |
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CCLD is still creating some value.
CCLD has more shares outstanding than it did 1 year ago.
CCLD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CCLD has been reduced compared to a year ago.
2.2 Solvency
CCLD has an Altman-Z score of 2.97. This is not the best score and indicates that CCLD is in the grey zone with still only limited risk for bankruptcy at the moment.
CCLD has a Altman-Z score of 2.97. This is in the better half of the industry: CCLD outperforms 72.97% of its industry peers.
CCLD has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
CCLD's Debt to FCF ratio of 0.03 is amongst the best of the industry. CCLD outperforms 89.19% of its industry peers.
CCLD has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CCLD has a Debt to Equity ratio of 0.00. This is in the better half of the industry: CCLD outperforms 72.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 2.97 |
ROIC/WACC1.31
WACC11.24%
2.3 Liquidity
CCLD has a Current Ratio of 1.27. This is a normal value and indicates that CCLD is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.27, CCLD perfoms like the industry average, outperforming 43.24% of the companies in the same industry.
CCLD has a Quick Ratio of 1.24. This is a normal value and indicates that CCLD is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.24, CCLD perfoms like the industry average, outperforming 43.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
CCLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.79%, which is quite impressive.
CCLD shows a decrease in Revenue. In the last year, the revenue decreased by -5.32%.
Measured over the past years, CCLD shows a quite strong growth in Revenue. The Revenue has been growing by 11.47% on average per year.
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%350%
Revenue 1Y (TTM)-5.32%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%6.42%
3.2 Future
Based on estimates for the next years, CCLD will show a very strong growth in Earnings Per Share. The EPS will grow by 74.27% on average per year.
Based on estimates for the next years, CCLD will show a small growth in Revenue. The Revenue will grow by 3.57% on average per year.
EPS Next Y157.8%
EPS Next 2Y74.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.38%
Revenue Next 2Y3.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CCLD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 9.06, the valuation of CCLD can be described as very reasonable.
97.30% of the companies in the same industry are more expensive than CCLD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of CCLD to the average of the S&P500 Index (20.35), we can say CCLD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.06 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCLD indicates a rather cheap valuation: CCLD is cheaper than 100.00% of the companies listed in the same industry.
CCLD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CCLD is cheaper than 97.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.01 | ||
| EV/EBITDA | 3.09 |
4.3 Compensation for Growth
CCLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CCLD's earnings are expected to grow with 74.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.27%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CCLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.88
-0.26 (-12.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners11.24%
Inst Owner ChangeN/A
Ins Owners37.42%
Ins Owner Change6.3%
Market Cap79.56M
Analysts82
Price Target4.25 (126.06%)
Short Float %0.86%
Short Ratio0.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.92
Dividend Growth(5Y)21.2%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)85.74%
Min EPS beat(2)71.48%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)-23.2%
Min EPS beat(4)-357.52%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)-17.94%
EPS beat(12)8
Avg EPS beat(12)-3.5%
EPS beat(16)12
Avg EPS beat(16)5.11%
Revenue beat(2)0
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)-1.1%
Revenue beat(4)0
Avg Revenue beat(4)-1.81%
Min Revenue beat(4)-2.28%
Max Revenue beat(4)-1.1%
Revenue beat(8)0
Avg Revenue beat(8)-4.44%
Revenue beat(12)1
Avg Revenue beat(12)-3.54%
Revenue beat(16)3
Avg Revenue beat(16)-2.25%
PT rev (1m)-4.28%
PT rev (3m)-18.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.54%
EPS NY rev (1m)0%
EPS NY rev (3m)155.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.06 | ||
| P/S | 0.72 | ||
| P/FCF | 6.01 | ||
| P/OCF | 3.85 | ||
| P/B | 1.6 | ||
| P/tB | 6.69 | ||
| EV/EBITDA | 3.09 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.21
Fwd EY11.03%
FCF(TTM)0.31
FCFY16.64%
OCF(TTM)0.49
OCFY25.94%
SpS2.62
BVpS1.18
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -6.33% | ||
| ROCE | 18.67% | ||
| ROIC | 14.75% | ||
| ROICexc | 16.37% | ||
| ROICexgc | 85.25% | ||
| OM | 8.77% | ||
| PM (TTM) | N/A | ||
| GM | 45.11% | ||
| FCFM | 11.94% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y52.71%
ROICexcg growth 5Y104.32%
ROICexc growth 3Y91.65%
ROICexc growth 5Y92.03%
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
F-Score7
Asset Turnover1.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 51.19% | ||
| Cap/Sales | 6.68% | ||
| Interest Coverage | 14.35 | ||
| Cash Conversion | 85.35% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 2.97 |
F-Score7
WACC11.24%
ROIC/WACC1.31
Cap/Depr(3y)74.91%
Cap/Depr(5y)76.9%
Cap/Sales(3y)8.36%
Cap/Sales(5y)8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%350%
EPS Next Y157.8%
EPS Next 2Y74.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.32%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%6.42%
Revenue Next Year1.38%
Revenue Next 2Y3.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y342.44%
EBIT growth 3Y47.96%
EBIT growth 5Y117.42%
EBIT Next Year214.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y243.97%
FCF growth 3Y68.43%
FCF growth 5Y21.21%
OCF growth 1Y33.51%
OCF growth 3Y15.69%
OCF growth 5Y22.06%